No Data
No Data
Does Mirum Pharmaceuticals (NASDAQ:MIRM) Have A Healthy Balance Sheet?
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $74
Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus
Express News | Livmarli Now Approved in Japan for Algs and Pfic
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $65